Australian Institute of Health and Welfare (2020) Alcohol and other drug treatment services in Australia 2018–19, AIHW, Australian Government, accessed 26 March 2023.
Australian Institute of Health and Welfare. (2020). Alcohol and other drug treatment services in Australia 2018–19. Canberra: AIHW.
Australian Institute of Health and Welfare. Alcohol and other drug treatment services in Australia 2018–19. AIHW, 2020.
Australian Institute of Health and Welfare. Alcohol and other drug treatment services in Australia 2018–19. Canberra: AIHW; 2020.
Australian Institute of Health and Welfare 2020, Alcohol and other drug treatment services in Australia 2018–19, AIHW, Canberra.
PDF | 2.9Mb
Other formats
In 2018–19, 1,283 publicly funded alcohol and other drug (AOD) treatment services provided just under 220,000 treatment episodes to an estimated 137,000 clients. The four most common drugs that led clients to seek treatment for their own drug use were alcohol (36% of all treatment episodes), amphetamines (28%), cannabis (20%) and heroin (5%). Almost two-thirds (64%) of all clients receiving treatment were male, and the median age of clients was 34 years.
To learn more, see Alcohol and other drug treatment services in Australia 2018–19: key findings.
Note: Content was updated to include 2019 National Drug Strategy Household Survey data on 6 Nov 2020.
COVID-19 This release covers data up to 30 June 2019, preceding COVID-19.
Alcohol and other drug (AOD) treatment services across Australia provide a broad range of treatment services and support to people who use alcohol or drugs, and to their families and friends. This report presents information for 2018–19 about publicly funded AOD treatment service agencies, the people they treat and the treatment provided.
In 2018–19:
Alcohol, cannabis, amphetamines and heroin have remained the most common principal drugs of concern for clients since the beginning of the collection.
In 2018–19, among clients seeking treatment for their own alcohol or drug use:
Over the 10-year period to 2018–19:
where amphetamines were the principal drug of concern, the number of episodes where the method of use was smoking, inhaling, or injecting increased over 6-fold, from around 8,000 episodes in 2009–10 to 52,200 episodes in 2018–19
Since 2009–10 the proportion of episodes for each of the four most common main treatment types have fluctuated.
2. Agencies
End matter: Acknowledgments; Abbreviations; Symbols; Glossary; References; List of tables; List of figures; List of boxes
This website needs JavaScript enabled in order to work correctly; currently it looks like it is disabled. Please enable JavaScript to use this website as intended.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.
The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.